Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a ...

A simple urine test could accurately show the recurrence of kidney cancer at an early stage, potentially sparing patients ...

CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the successful completion of the first dose, ...

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

Hi, everyone, and welcome to the next episode of our CEO Fireside Chats. My name is David Bautz and I'm a senior biotechnology analyst here at Zacks Small Cap Research. Joining me today is Chris ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...

A cardiologist testified that Diego Maradona was considered a “high-risk patient” and said that the authorities at the clinic where he underwent surgery days before his death recommended that the ...

Despite widespread vaccine availability and improved treatment strategies, certain patients with SARDs remain highly vulnerable to severe COVID-19 outcomes.

Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.

Accurate risk profile assessments can help you maintain trust. Here’s a step-by-step guide to ensure your client relationships survive a market crash, including key talking points. 1.